Harrow Stock Falls After 3Q Earnings, Revenue Miss Estimates

Dow Jones11-11

By Kelly Cloonan

Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product.

The stock declined 7.7% to $31.50 in after-hours trading on Monday. Through market close, shares are up 1.8% this year.

The disease management solutions provider posted a third-quarter profit of $1 million, or 3 cents a share, compared with a loss of $4.2 million, or 12 cents a share, a year earlier. Analysts expected earnings of 22 cents a share, according to FactSet.

Adjusted earnings per share were 33 cents, topping estimates of 29 cents a share according to analysts polled by FactSet.

Revenue jumped 45% to $71.6 million, missing analyst expectations of $73.7 million.

Chief Executive Mark Baum said the results were driven in part by worse-than-expected performance for Triesence, a steroid used to treat several eye diseases.

Still, Baum expects the product will become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market, he said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

November 10, 2025 18:10 ET (23:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582670389?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582670389","market":"sh","top_or_hot":-1,"title":"Harrow Stock Falls After 3Q Earnings, Revenue Miss Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product. \n</p>\n<p>\n  The stock declined 7.7% to $31.50 in after-hours trading on Monday. Through market close, shares are up 1.8% this year. \n</p>\n<p>\n  The disease management solutions provider posted a third-quarter profit of $1 million, or 3 cents a share, compared with a loss of $4.2 million, or 12 cents a share, a year earlier. Analysts expected earnings of 22 cents a share, according to FactSet. \n</p>\n<p>\n  Adjusted earnings per share were 33 cents, topping estimates of 29 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue jumped 45% to $71.6 million, missing analyst expectations of $73.7 million. \n</p>\n<p>\n  Chief Executive Mark Baum said the results were driven in part by worse-than-expected performance for Triesence, a steroid used to treat several eye diseases. \n</p>\n<p>\n  Still, Baum expects the product will become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market, he said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harrow Stock Falls After 3Q Earnings, Revenue Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarrow Stock Falls After 3Q Earnings, Revenue Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-11 07:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product. \n</p>\n<p>\n  The stock declined 7.7% to $31.50 in after-hours trading on Monday. Through market close, shares are up 1.8% this year. \n</p>\n<p>\n  The disease management solutions provider posted a third-quarter profit of $1 million, or 3 cents a share, compared with a loss of $4.2 million, or 12 cents a share, a year earlier. Analysts expected earnings of 22 cents a share, according to FactSet. \n</p>\n<p>\n  Adjusted earnings per share were 33 cents, topping estimates of 29 cents a share according to analysts polled by FactSet. \n</p>\n<p>\n  Revenue jumped 45% to $71.6 million, missing analyst expectations of $73.7 million. \n</p>\n<p>\n  Chief Executive Mark Baum said the results were driven in part by worse-than-expected performance for Triesence, a steroid used to treat several eye diseases. \n</p>\n<p>\n  Still, Baum expects the product will become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market, he said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 10, 2025 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582670389","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582670389","pubTimestamp":1762816200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product.The stock declined 7.7% to $31.50 in after-hours trading on Monday. Through market close, shares are up 1.8% this year.The disease management solutions provider posted a third-quarter profit of $1 million, or 3 cents a share, compared with a loss of $4.2 million, or 12 cents a share, a year earlier. Analysts expected earnings of 22 cents a share, according to FactSet.Adjusted earnings per share were 33 cents, topping estimates of 29 cents a share according to analysts polled by FactSet.Revenue jumped 45% to $71.6 million, missing analyst expectations of $73.7 million.Chief Executive Mark Baum said the results were driven in part by worse-than-expected performance for Triesence, a steroid used to treat several eye diseases.Still, Baum expects the product will become the leading ophthalmic injectable steroid in the U.S. market as it ga","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc","BK4007":"制药","BK4557":"大麻股"},"translate_title":"哈罗股价在第三季度盈利后下跌，收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product. \n\n\n  The stock declined 7.7% to $31.50 in after-hours trading on Monday. Through market close, shares are up 1.8% this year. \n\n\n  The disease management solutions provider posted a third-quarter profit of $1 million, or 3 cents a share, compared with a loss of $4.2 million, or 12 cents a share, a year earlier. Analysts expected earnings of 22 cents a share, according to FactSet. \n\n\n  Adjusted earnings per share were 33 cents, topping estimates of 29 cents a share according to analysts polled by FactSet. \n\n\n  Revenue jumped 45% to $71.6 million, missing analyst expectations of $73.7 million. \n\n\n  Chief Executive Mark Baum said the results were driven in part by worse-than-expected performance for Triesence, a steroid used to treat several eye diseases. \n\n\n  Still, Baum expects the product will become the leading ophthalmic injectable steroid in the U.S. market as it gains traction in the eye inflammation market, he said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 18:10 ET (23:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582670389","isCrawlerRequest":true}